PD01-04 ANTIMICROBIAL PEPTIDE, BETA-DEFENSIN 2 (BD2), IS A NOVEL BIOMARKER ON ULCERATIVE INTERSTITIAL CYSTITIS; CAN BD2 SUSPECT THE DYSBIOSIS OF URINE MICROBIOTA?

Abstract

You have accessJournal of UrologyInfections/Inflammation/Cystic Disease of the Genitourinary Tract: Interstitial Cystitis (PD01)1 Sep 2021PD01-04 ANTIMICROBIAL PEPTIDE, BETA-DEFENSIN 2 (BD2), IS A NOVEL BIOMARKER ON ULCERATIVE INTERSTITIAL CYSTITIS; CAN BD2 SUSPECT THE DYSBIOSIS OF URINE MICROBIOTA? Sang Wook Lee, Woong Bin Kim, Si Hyun Kim, Ji Kang Yun, and Young Ho Kim Sang Wook LeeSang Wook Lee More articles by this author , Woong Bin KimWoong Bin Kim More articles by this author , Si Hyun KimSi Hyun Kim More articles by this author , Ji Kang YunJi Kang Yun More articles by this author , and Young Ho KimYoung Ho Kim More articles by this author View All Author Informationhttps://doi.org/10.1097/JU.0000000000001965.04AboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareFacebookLinked InTwitterEmail Abstract INTRODUCTION AND OBJECTIVE: Since urine is not sterile, inflammatory reactions caused by dysbiosis of urinary microbiota may induce interstitial cystitis. A study was conducted to find out whether BD2, one of antimicrobial peptides in urine, could be used as a novel diagnostic marker for ulcerative interstitial cystitis (IC), compared to macrophage migration inhibitory factor (MIF). METHODS: Urine samples were assayed for BD2 and MIF by enzyme-linked immunosorbent assays (ELISA). Urine samples from three female groups were examined: healthy controls (N=34, Group I), non-ulcerative IC (N=40, Group II), and ulcerative IC (N=68, Group III). Urine samples were collected via transurethral catheter all patients with IC. Cystoscopy with diagnostic and therapeutic hydrodistention was applied a to Group II & III patients. The National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK) criteria were applied to the patients with endoscopic clinical diagnosis of Painful bladder syndrome/IC. The mast cell counts criteria proposed by the European Society for the Study of Interstitial Cystitis (ESSIC) were contrasted and results were compared. RESULTS: Based on urinary specimens from a total of 142 patients, BD2 expressed 18-fold higher in patients with ulcerative IC than in patients with non-ulcerative IC. MIF levels were 31-fold higher in patients with ulcerative IC than in patients with non-ulcerative IC. The enhanced secretion of BD-2 exhibited a strong correlation with the increased mast cell counts associated with bladder IC pathology. CONCLUSIONS: Enhanced urinary secretion of BD2 from ulcerative IC patients demonstrated relatively robust levels to be used as potential biomarkers, and associated with clinical phenotypes. Moreover, the increased urinary level of anti-microbial peptide BD2 may suggest a new possibility of diagnosis caused by dysbiosis of urinary microbiota in ulcerative IC. Source of Funding: This work was supported by the “Soonchunhyang University Research Fund” © 2021 by American Urological Association Education and Research, Inc.FiguresReferencesRelatedDetails Volume 206Issue Supplement 3September 2021Page: e31-e32 Advertisement Copyright & Permissions© 2021 by American Urological Association Education and Research, Inc.MetricsAuthor Information Sang Wook Lee More articles by this author Woong Bin Kim More articles by this author Si Hyun Kim More articles by this author Ji Kang Yun More articles by this author Young Ho Kim More articles by this author Expand All Advertisement Loading ...